ABL1 and synucleinopathy: New therapeutics aiming at disease-modification in synucleinopathies in the clinical development stage can currently be grouped regarding mode of action as I) interventions preventing α-synuclein aggregation or dissolving aggregates, II) interventions that reduce α-synuclein expression20 or affect α-synuclein metabolism and clearance (LRRK2 inactivation and reduction of LRRK2 gene expression,21 c-Abl- inhibition, mTOR–inhibition, and increase of lysosomal activity via stimulation of GBA.5